• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ascentage Pharma Group International - American Depository Shares (NQ:AAPG)

    19.40 -0.78 (-3.87%)
    Streaming Delayed Price Updated: 11:44 AM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ascentage Pharma Group International - American Depository Shares

    < Previous 1 2 Next >
    News headline image
    Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Participate in Three Upcoming Investor Conferences
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Participate in Three Upcoming Investor Conferences
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
     
    Via Benzinga
    News headline image
    This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday ↗
     
    Via Benzinga
    News headline image
    Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For August 20, 2025 ↗
     
    Via Benzinga
    News headline image
    US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns' ↗
    U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading mixed. 
    Via Benzinga
    Topics Artificial Intelligence Government
    News headline image
    Penguin Solutions, Merit Medical Systems And 3 Stocks To Watch Heading Into Tuesday ↗
     
    Via Benzinga
    News headline image
    Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? ↗
    Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics. 
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday ↗
     
    Via Benzinga
    News headline image
    Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan ↗
    JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment. 
    Via Benzinga
    News headline image
    Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For March 27, 2025 ↗
     
    Via Benzinga
    News headline image
    Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
    From ASCENTAGE PHARMA GROUP INTERNATIONAL
    Via GlobeNewswire
    News headline image
    IPO Momentum Builds In 2025: Diginex, CTRL Group, And Others Post Strong Gains ↗
    US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more growth as 36 IPOs have already been priced this year, including Diginex's 600%... 
    Via Benzinga
    Topics Initial Public Offering
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.